The research, published in July in Transplantation and Cellular Therapy, found that factors like age, race, and income impact whether patients receive these therapies. Surprisingly, proximity to a treatment center also played a crucial role. The FDA mandates that patients remain near the treatment center for 4 weeks after treatment and refrain from driving for 8 weeks. Their study showed that older patients were less likely to receive CAR T, with the likelihood decreasing by 4% for each year increase in age. There was also a trend toward Hispanic patients being less likely to receive CAR T, although this did not reach statistical significance.

Source: New York Times October 13, 2024 16:52 UTC